Articles

antiplatelet medication, prasugrel, clopidogrel, risk algorithm, SCAI

A risk assessment algorithm combining clinical risk factors and platelet function test results may help interventional cardiologists better identify patients who stand to benefit from intensive...

PROMETHEUS, prasugrel, clopidogrel, heart disease, bleeding, SCAI

Prasugrel (Effient) is more likely to be given to lower-risk heart disease patients undergoing percutaneous coronary intervention (PCI) compared to clopidogrel, according to a new study. Results...

heart stent, OAP therapy, ACS, patients, PCNA, SCAI, medication, prescribed

People with acute coronary syndrome (ACS) who undergo an angioplasty procedure and receive a heart stent are prescribed an oral antiplatelet (OAP) therapy and aspirin to help prevent a heart...

The Medicines Company, cangrelor, FDA advisory committee, approval

The Medicines Company announced that the U.S. Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 9 - 2 with one abstention to recommend approval of...

ivabradine (Corlanor)

The U.S. Food and Drug Administration (FDA) approved Amgen’s ivabradine (Corlanor) to reduce hospitalization from worsening heart failure.

Adding the antiplatelet drug ticagrelor (Brilinta) to aspirin as long-term therapy after a heart attack significantly reduced the rate of subsequent death from cardiovascular causes, heart attack...

A novel therapy that would allow doctors to turn the body’s blood clotting ability off and on in a more controlled way was about as effective as established anticoagulants in patients undergoing...

atients with acute coronary syndrome undergoing angioplasty who received the anticoagulant drug bivalirudin did not show significant improvements in either of two coprimary endpoints — a composite...

dual antiplatelet therapy, DAPT, mortality, DES implantation, CRF, length

Data from a meta-analysis published recently in The Lancet found that extended-duration dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation was associated with...

Boston Scientific, Watchman LAA device, FDA approval

Boston Scientific Corp. has received U.S. Food and Drug Administration (FDA) approval for the Watchman left atrial appendage closure device. The Watchman device offers a new stroke risk reduction...